Cargando…
Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials
PURPOSE: Nitazoxanide is a broad-spectrum antiparasitic that has been tested for COVID-19 due to its anti-inflammatory effects and in vitro antiviral activity. This study synthesized the best evidence on the efficacy and safety of nitazoxanide in COVID-19. METHODS: Searches for studies were performe...
Autores principales: | Martins-Filho, Paulo Ricardo, do Nascimento-Júnior, Edmundo Marques, Barreto-Alves, José Antônio, Fakhouri, Ricardo, Ferreira, Lis Campos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446612/ https://www.ncbi.nlm.nih.gov/pubmed/36066651 http://dx.doi.org/10.1007/s00228-022-03380-5 |
Ejemplares similares
-
Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.
por: Martins-Filho, Paulo Ricardo, et al.
Publicado: (2021) -
Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.
por: Blum, Vinicius Fontanesi, et al.
Publicado: (2021) -
Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
por: Rocco, Patricia R. M., et al.
Publicado: (2022) -
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial
por: Rocco, Patricia R.M., et al.
Publicado: (2021) -
Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
por: Blum, Vinicius Fontanesi, et al.
Publicado: (2021)